TA-TMA and GVHD are distinct consequences of endothelial injury: A MIDAS consortium study [0.03%]
内皮损伤导致TA-TMA和GVHD是两种不同的后果：MIDAS联盟研究
Theresa Hahn,Qiuhong Zhao,Elizabeth Greer Miller et al.
Theresa Hahn et al.
Graft-versus-host disease (GVHD) is a major risk factor for transplant-associated thrombotic microangiopathy (TA-TMA), and the two conditions often co-occur; therefore, we evaluated biomarkers of endothelial injury to clarify their relation...
Targeting BCMA in Patients with Relapsed/Refractory Multiple Myeloma in 1-3 Prior Lines of Therapy [0.03%]
靶向BCMA治疗复发/难治多发性骨髓瘤（既往使用过1-3线治疗的患者）
Doris K Hansen,Maria-Victoria Mateos,Luciano J Costa
Doris K Hansen
The treatment landscape for multiple myeloma is evolving rapidly with the integration of novel BCMA-directed therapies. In the early relapse setting (1-3 prior lines of therapy), several practice-changing phase 3 trials have reported result...
Naif I Aljohani
Naif I Aljohani
Real-World Treatment Patterns of Patients with Large B-cell Lymphoma Over Time and into a Post-CAR T Approval Era [0.03%]
CAR-T审批后时代大型B细胞淋巴瘤患者的治疗模式及其演变趋势
Miguel-Angel Perales,Joseph P McGuirk,Mark R Fesen et al.
Miguel-Angel Perales et al.
A significant proportion of patients with large B-cell lymphoma (LBCL) experience relapsed or refractory (R/R) disease after first-line therapy. Chimeric antigen receptor T-cell (CAR T) therapy is approved for R/R LBCL, yet real-world utili...
Carfilzomib plus induction chemotherapy in children with relapsed or refractory acute lymphoblastic leukemia [0.03%]
卡非佐米联合诱导化疗治疗复发或难治性急性淋巴细胞白血病患儿的效果
Franco Locatelli,Musa Karakukcu,Van Huynh et al.
Franco Locatelli et al.
We report outcomes of the phase 2 study combining carfilzomib (CFZ) plus vincristine, dexamethasone, asparaginase, and daunorubicin (CFZ-VXLD) in heavily pre-treated, pediatric patients with relapsed/refractory (R/R) acute lymphoblastic leu...
John Mascarenhas
John Mascarenhas
CAR in R/R FL: is real-world efficacy meeting expectations? [0.03%]
复发/难治性FL中使用CAR T疗法：现实世界的疗效符合预期吗？
Estelle Bourbon,Emmanuel Bachy
Estelle Bourbon
Zhang B, Xie Y, Shen M, et al. Multiplexed imaging mass cytometry elicits p-S6 as a therapeutic and prognostic factor in diffuse large B-cell lymphoma. Blood Adv. 2025;9(13):3249-3262 [0.03%]
张斌，谢宇，沈梅，等。成像质量细胞计促进p-s6作为弥漫性大B细胞淋巴瘤的治疗和预后因素。Blood Adv. 2025;9(13):3249-3262
Published Erratum
Blood advances. 2026 Jun 9;10(11):3832. DOI:10.1182/bloodadvances.2026020555 2026
Cost-effectiveness of iron deficiency screening in pregnancy across ferritin-based thresholds [0.03%]
基于血清铁蛋白的孕期铁缺乏筛查的成本效益分析
Daniel Wang,Manraj Singh Sra,Ding Quan Ng et al.
Daniel Wang et al.
Maternal iron deficiency (ID) affects nearly 85% of all pregnancies worldwide by the third trimester and is significantly linked with maternal morbidity, poor birth outcomes, and cognitive and behavioral developmental deficits in children. ...
Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study [0.03%]
获得性PRCA的临床异质性和结局：一项欧洲多中心研究
Francesco Versino,Marc Michel,Jennifer Vidler et al.
Francesco Versino et al.
Pure red cell aplasia (PRCA) is a rare single lineage bone marrow failure defined by anemia with profound reticulocytopenia and severe reduction of erythroid precursors. Clinical spectrum is heterogeneous, and diagnosis often requires exten...